Skip to main content

Table 1 Baseline Clinical Characteristics

From: Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions

Variables Overall population Matched population
PCB (n = 32) Non-PCB (n = 74) p PCB (n = 25) Non-PCB (n = 25) p
Age, years* 70.8 ± 7.2 76.7 ± 9.3 0.320 71.9 ± 7.5 71.5 ± 8.9 0.864
Male sex* 20 (62.5) 48 (64.9) 0.816 17 (68.0) 17 (68.0) 1.000
Body mass index, kg/m2* 23.8 ± 3.7 23.3 ± 3.5 0.531 23.4 ± 3.7 23.6 ± 2.4 0.770
Hypertension* 31 (96.9) 64 (86.5) 0.167 24 (96.0) 25 (100.0) 1.00
Diabetes mellitus* 26 (81.3) 49 (66.2) 0.163 19 (76.0) 17 (68.0) 0.754
Dyslipidemia* 15 (46.9) 37 (50.0) 0.768 11 (44.0) 13 (52.0) 0.571
Current smoker* 8 (25.0) 15 (20.3) 0.614 5 (20.0) 5 (20.0) 1.000
Chronic kidney disease* 11 (34.4) 32 (43.2) 0.391 9 (36.0) 7 (28.0) 0.762
Hemodialysis* 2 (6.3) 11 (14.9) 0.336 2 (8.0) 2 (8.0) 1.000
Rutherford class*    0.067    1.000
 2/3 31 (96.9) 62 (83.8)   24 (96.0) 25 (100.0)  
 4 1 (3.1) 7 (9.5)   1 (4.0) 0 (0.0)  
 5 0 (0.0) 5 (6.8)   0 (0.0) 0 (0.0)  
Ankle brachial index 0.63 ± 0.12 0.60 ± 0.15 0.375 0.62 ± 0.13 0.61 ± 0.11 0.792
Medication at treatment of ISR
 Aspirin 29 (90.6) 67 (90.5) 1.000 22 (88.0) 24 (96.0) 0.609
 P2Y12 antagonist 21 (65.6) 52 (70.3) 0.637 16 (64.0) 13 (52.0) 0.567
 Cilostazol 15 (46.9) 30 (40.5) 0.546 13 (52.0) 13 (52.0) 1.000
 Oral anticoagulant 2 (6.3) 14 (18.9) 0.140 2 (8.0) 5 (20.0) 0.417
  1. Categorical variables are expressed as number and percentage. Continuous variables are indicated as mean ± SD
  2. ISR indicates in-stent restenosis, PCB paclitaxel-coated balloon
  3. *Variables included in the multivariable analysis to estimate propensity score